Presage Biosciences Announces Strategic Research Alliance with Celgene
-- Partnership Employs Presage's Innovative Platform to Accelerate
Identification of Novel Oncology Drug Combinations for Patients with Solid
SEATTLE, March 5, 2013
SEATTLE, March 5, 2013 /PRNewswire/ -- Presage Biosciences, a leader in
discovering effective cancer drug combinations, today announced that it has
entered into a strategic collaboration agreement with Celgene Corporation
under which Presage and Celgene will take advantage of Presage's proprietary
technology platform to identify novel drug combinations for solid tumor
The Presage platform is the only technology that allows for the direct
comparison of multiple drugs or drug combinations in the same living tumor. In
addition to identifying combination treatments for cancer, the company
ultimately intends to utilize its platform to precisely evaluate patients'
unique responses to microdoses of multiple cancer drugs.
Under the terms of the agreement, Presage will receive an upfront payment, an
equity investment, and will be eligible for downstream payments.
"Drug development is currently challenged by heavy reliance on in vitro test
systems and animal xenografts of little relevance to individual patients,"
said Thomas Daniel, M.D. Celgene President, Research and Early Development.
"The Presage platform addresses this challenge, permitting rapid assessment of
drug candidates and combinations in relevant models, with potential to base
critical drug development decisions on in vivo response data."
"Celgene is an ideal strategic partner for Presage.The two companies are well
aligned in focusing on original approaches to cancer drug discovery," said
Nathan Caffo, President of Presage Biosciences. "The innovative structure of
this research collaboration will enable us to continue our plan to expand the
application of the Presage platform, which offers fundamental insights into
novel cancer drug combinations and drug effects in living tumors."
About the Presage Platform
Presage Biosciences' patented drug array platform offers an unprecedented
method for simultaneously analyzing multiple cancer drug candidates and drug
combinations within a single living tumor.The Presage drug array platform
enables the precise placement of multiple microdoses of candidate treatments
through the skin and directly into a tumor. Such a controlled localization
enables drug-specific responses to be measured within an array of multiple
drugs. These three dimensionally delivered microdoses also provide the ability
to analyze drug effects across the span of a living tumor while capturing the
heterogeneity of cancer cells.
Celgene Corporation, headquartered inSummit, New Jersey, is an integrated
global biopharmaceutical company engaged primarily in the discovery,
development and commercialization of novel therapies for the treatment of
cancer and inflammatory diseases through gene and protein regulation. For more
information, please visit the company's Web site at www.celgene.com.
About Presage Biosciences
Presage Biosciences is driving discovery of effective drug combinations.The
company is dedicated to improving cancer drug development so that patients can
receive the most effective treatment possible. Presage partners with
oncology-focused pharmaceutical companies through strategic alliances to
provide previously inaccessible in vivo data to validate novel targets,
promote drug candidates to the right indications, and discover effective drug
combinations. Presage has developed the world's only known technology to
perform simultaneous comparisons of multiple drugs within a living tumor.
Presage is privately held and based in Seattle. For more information, visit
SOURCE Presage Biosciences
Contact: Julie Rathbun, Rathbun Communications, +1-206-769-9219,
Press spacebar to pause and continue. Press esc to stop.